Yadav Ekta, Tekkalaki Bheemsain, Gadadavar Kavita P, Yadawad Vishwas, Chate Sameeran S, Patil Sandeep, Koparde Vinayak
Dept. of KAHER's Psychiatry, Jawaharlal Nehru Medical College, Belagavi, Karnataka, India.
Indian J Psychol Med. 2025 Apr 29:02537176251334446. doi: 10.1177/02537176251334446.
Major depressive disorder (MDD) is a debilitating mental health condition characterized by significant morbidity and mortality. The emergence of ketamine infusion therapy has provided a promising, rapidly acting treatment option. We aimed to assess the effectiveness of ketamine infusion therapy as an adjunct treatment in patients with depression and to study the patient's profile undergoing ketamine therapy in a real-world clinical setting.
This was a retrospective chart review. A total of 28 patients with depression who received ketamine infusion therapy at a tertiary care hospital were included in this retrospective analysis. The Hamilton Depression Rating Scale (HAMD) was utilized to assess depressive symptomatology.
A statistically significant reduction in HAMD scores was observed post-treatment ( < .0001). Notably, 53.6% of patients achieved a therapeutic response (≥50% decrease in HAMD score), while 39.3% attained remission (HAMD score < 7) after an average of 4.6 ketamine infusions. Furthermore, a substantial decrease in suicidal ideation was observed in 71.4% of patients.
The finding of this study indicates that ketamine infusion therapy is safe and effective as a rapidly acting adjunct treatment for depression.
重度抑郁症（MDD）是一种使人衰弱的心理健康状况，具有显著的发病率和死亡率。氯胺酮输注疗法的出现提供了一种有前景的、起效迅速的治疗选择。我们旨在评估氯胺酮输注疗法作为抑郁症患者辅助治疗的有效性，并在真实临床环境中研究接受氯胺酮治疗的患者特征。
这是一项回顾性病历审查。本回顾性分析纳入了在一家三级护理医院接受氯胺酮输注疗法的28例抑郁症患者。采用汉密尔顿抑郁量表（HAMD）评估抑郁症状。
治疗后观察到HAMD评分有统计学意义的降低（<.0001）。值得注意的是，53.6%的患者获得了治疗反应（HAMD评分降低≥50%），而平均4.6次氯胺酮输注后，39.3%的患者达到缓解（HAMD评分<7）。此外，71.4%的患者自杀意念显著降低。
本研究结果表明，氯胺酮输注疗法作为抑郁症的一种起效迅速的辅助治疗是安全有效的。
